Varian and Proxima increase access to partial breast irradiation

TriMed Staff | | Health Imaging | Diagnostic Imaging
Varian Medical Systems Inc. and Proxima Therapeutics Inc. this week solidified an alliance to increase access to high-dose-rate (HDR) radiation therapy equipment for hospitals interested in offering partial breast irradiation to patients with early-stage breast cancer.

Under the terms of the agreement, Proxima will become the exclusive third-party representative for Varian's recently FDA-cleared MammoSource HDR brachytherapy afterloader, developed specifically to work with Proxima's MammoSite device for treating breast cancer with localized HDR brachytherapy. Varian's MammoSource afterloader will be made available to treatment centers on a fee-for-use basis, subject to minimums.

According to Varian, the MammoSource afterloader is more affordable than traditional HDR afterloaders, which incorporate up to 24 channels for delivering more complex forms of brachytherapy. Varian developed the MammoSource HDR afterloader to deliver radiation through a single channel, consistent with MammoSite's single balloon catheter design. MammoSource is powered by Varian's BrachyVision software, HDR brachytherapy treatment planning system.

TriMed Staff

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup